Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications

Area of Science:

• Cardiovascular Biology
• Endocrinology
• Molecular Medicine

Background:

• Hyperglycemia is a primary driver of endothelial dysfunction in diabetes mellitus.
• The diacylglycerol (DAG)-protein kinase C (PKC) pathway is implicated in mediating this dysfunction.
• PKC activation leads to adverse vascular effects, including oxidative stress and impaired nitric oxide (NO) signaling.

Purpose of the Study:

• To elucidate the role of the DAG-PKC pathway in hyperglycemia-induced endothelial dysfunction.
• To investigate the therapeutic potential of PKC inhibitors in mitigating vascular complications of diabetes.

Main Methods:

• In vivo and in vitro studies examining the DAG-PKC pathway.
• Analysis of PKC isoform activation, specifically beta-isoforms.
• Evaluation of PKC inhibitors (selective and non-selective) in experimental models and patient studies.

Main Results:

• PKC activation contributes to endothelial dysfunction by increasing NADPH oxidase activity and uncoupled eNOS.
• PKC-mediated superoxide production inactivates nitric oxide (NO) and inhibits soluble guanylyl cyclase.
• PKC inhibitors demonstrated beneficial effects on glucose-induced endothelial dysfunction in animal models and human patients.

Conclusions:

• The DAG-PKC pathway is a critical mediator of hyperglycemia-induced endothelial dysfunction.
• Targeting PKC with inhibitors offers a promising therapeutic strategy for preventing and treating vascular complications in diabetes.